Photo from wikipedia
Results from a retrospective cohort study suggest that use of a disease activityguided dose optimization (DAGDO) strategy to taper TNF inhibitor therapy is safe and effective in patients with psoriatic… Click to show full abstract
Results from a retrospective cohort study suggest that use of a disease activityguided dose optimization (DAGDO) strategy to taper TNF inhibitor therapy is safe and effective in patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) and low disease activity. The mean percentage of daily defined dose of TNF inhibitor was 108% in the fulldose period and 78% after DAGDO in those with PsA (n = 153; median followup period 46 months), and 108% in the fulldose period and 72% after DAGDO in those with axSpA (n = 171; median followup period 44 months), with no difference in disease activity scores.
Journal Title: Nature Reviews Rheumatology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!